middle.news
Radiopharm Theranostics Doses First Patient in RAD 402 Prostate Cancer Trial
8:34am on Friday 27th of March, 2026 AEDT
•
Healthcare
Read Story
Radiopharm Theranostics Doses First Patient in RAD 402 Prostate Cancer Trial
8:34am on Friday 27th of March, 2026 AEDT
Key Points
First patient dosed in Phase 1 trial of RAD 402
RAD 402 targets KLK3 with Terbium 161 radiolabel
Trial aims to establish safety, tolerability, and dosing
Preclinical studies show strong tumour targeting and minimal off-target effects
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Radiopharm Theranostics (ASX:RAD)
OPEN ARTICLE